There is a strong suggestion that imbalances of SphK1 isoform abundance may play a crucial role in the pathophysiology of diverse diseases, may contribute to resistance to current anti-cancer drug therapies [25–27], and may have consequences for therapies targeting SphK1 and S1P in the presence of comorbid conditions [15, 28]. This evidence concerns the gene MBTPS1 and cancer.